查看文章

Aging is considered one of the main predisposing factors for the development of prostate malignancies. Angiogenesis is fundamental for tumor growth and its inhibition represents a promising therapeutic approach in cancer treatment. Thus, we sought to determine angiogenic responses and the effects of antiangiogenic therapy in the mouse prostate during late life, comparing these findings with the prostatic microenvironment in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) model.

Male mice (52 week‐old FVB) were submitted to treatments with SU5416 (6 mg/kg; i.p.) and/or TNP‐470 (15 mg/kg; s.c.). Finasteride was administered (20 mg/kg; s.c.), alone or in association to both inhibitors. The dorsolateral prostate was collected for VEGF, HIF‐1α, FGF‐2 and endostatin immunohistochemical and Western Blotting analyses and for microvessel density (MVD) count …